ZA200702632B - Variants of hepatitus B virus with resistance to anti-viral nucleoside agents and applications thereof - Google Patents
Variants of hepatitus B virus with resistance to anti-viral nucleoside agents and applications thereofInfo
- Publication number
- ZA200702632B ZA200702632B ZA200702632A ZA200702632A ZA200702632B ZA 200702632 B ZA200702632 B ZA 200702632B ZA 200702632 A ZA200702632 A ZA 200702632A ZA 200702632 A ZA200702632 A ZA 200702632A ZA 200702632 B ZA200702632 B ZA 200702632B
- Authority
- ZA
- South Africa
- Prior art keywords
- viral
- variants
- present
- virus
- agents
- Prior art date
Links
- 239000003795 chemical substances by application Substances 0.000 title abstract 4
- 230000000840 anti-viral effect Effects 0.000 title abstract 2
- 239000002777 nucleoside Substances 0.000 title abstract 2
- 150000003833 nucleoside derivatives Chemical class 0.000 title abstract 2
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 title 1
- 230000003612 virological effect Effects 0.000 abstract 5
- 241000700721 Hepatitis B virus Species 0.000 abstract 3
- 238000003556 assay Methods 0.000 abstract 2
- 230000001747 exhibiting effect Effects 0.000 abstract 2
- 230000035945 sensitivity Effects 0.000 abstract 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 abstract 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 238000011285 therapeutic regimen Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5761—Hepatitis B
- G01N33/5764—Hepatitis B surface antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/44—Multiple drug resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2004905615A AU2004905615A0 (en) | 2004-09-28 | Viral variants and applications thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200702632B true ZA200702632B (en) | 2008-08-27 |
Family
ID=36118509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200702632A ZA200702632B (en) | 2004-09-28 | 2007-03-29 | Variants of hepatitus B virus with resistance to anti-viral nucleoside agents and applications thereof |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7927601B2 (xx) |
| EP (1) | EP1799814B1 (xx) |
| AT (1) | ATE503830T1 (xx) |
| DE (1) | DE602005027226D1 (xx) |
| WO (1) | WO2006034545A1 (xx) |
| ZA (1) | ZA200702632B (xx) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7405039B2 (en) | 2002-02-07 | 2008-07-29 | Austin Health | Viral variants with altered susceptibility to nucleoside analogs and uses thereof |
| WO2003087351A1 (en) | 2002-04-12 | 2003-10-23 | Melbourne Health | Hepatitis b viral variants with redused susceptibility to nucleoside analogs and uses thereof |
| AU2006230802A1 (en) | 2005-04-08 | 2006-10-12 | Austin Health | Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof |
| WO2006105597A1 (en) * | 2005-04-08 | 2006-10-12 | Melbourne Health | Variants of hepatitis b virus with resistance to anti-viral nucleoside agents and applications thereof |
| EP1948800B1 (en) * | 2005-10-21 | 2015-12-23 | Melbourne Health | Antiviral resistance mutants and applications thereof |
| CN101548014B (zh) * | 2006-06-06 | 2012-07-04 | 墨尔本保健公司 | 抗病毒抗性突变的检测和应用 |
| WO2011039612A1 (en) * | 2009-10-01 | 2011-04-07 | Ranjit Chauhan | Detection and use of antiviral resistance mutations |
| EA029137B1 (ru) | 2011-04-21 | 2018-02-28 | Ионис Фармасьютикалз, Инк. | Модулирование экспрессии вируса гепатита в (hbv) |
| CN102807971B (zh) * | 2011-06-09 | 2014-02-12 | 复旦大学附属华山医院 | 高表达耐拉米夫定hbv病毒肝癌细胞株 |
| EP3148566B1 (en) * | 2014-06-02 | 2024-04-03 | ISA Pharmaceuticals B.V. | Synthetic long peptides (slp) for therapeutic vaccination against hepatitis b virus infection |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2309379A1 (en) | 2000-06-09 | 2001-12-09 | Thomas Bock | Viral variants and uses therefor |
| JP4502642B2 (ja) * | 2002-02-07 | 2010-07-14 | メルボルン ヘルス | ヌクレオシドアナログに対する感受性の変化を有するウイルス変種およびその使用 |
| WO2003087351A1 (en) * | 2002-04-12 | 2003-10-23 | Melbourne Health | Hepatitis b viral variants with redused susceptibility to nucleoside analogs and uses thereof |
| EP1546190A2 (en) | 2002-10-01 | 2005-06-29 | Gilead Sciences, Inc. | Hbv mutations associated with reduced susceptibility to adefovir |
| JP2007509614A (ja) | 2003-10-21 | 2007-04-19 | メルボルン ヘルス | Ｈｂｖ変種の検出および適用 |
-
2005
- 2005-09-28 WO PCT/AU2005/001489 patent/WO2006034545A1/en active Application Filing
- 2005-09-28 EP EP05791326A patent/EP1799814B1/en not_active Not-in-force
- 2005-09-28 AT AT05791326T patent/ATE503830T1/de not_active IP Right Cessation
- 2005-09-28 DE DE602005027226T patent/DE602005027226D1/de active Active
- 2005-09-28 US US11/576,249 patent/US7927601B2/en not_active Expired - Fee Related
-
2007
- 2007-03-29 ZA ZA200702632A patent/ZA200702632B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1799814A1 (en) | 2007-06-27 |
| US20100047281A1 (en) | 2010-02-25 |
| EP1799814B1 (en) | 2011-03-30 |
| US7927601B2 (en) | 2011-04-19 |
| ATE503830T1 (de) | 2011-04-15 |
| DE602005027226D1 (de) | 2011-05-12 |
| EP1799814A4 (en) | 2008-02-20 |
| WO2006034545A1 (en) | 2006-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200702632B (en) | Variants of hepatitus B virus with resistance to anti-viral nucleoside agents and applications thereof | |
| Ning et al. | Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial) | |
| SG161255A1 (en) | Variants of hepatitis b virus with resistance to anti-viral nucleoside agents and applications thereof | |
| Hatzakis et al. | HBV virological assessment | |
| EP1476543A4 (en) | VIRUS VARIANTS WITH CHANGED SENSITIVITY TO NUCLEOSIDANALOGES AND USES THEREOF | |
| Guirgis et al. | Hepatitis B virus genotyping: current methods and clinical implications | |
| Lok et al. | Antiviral drug‐resistant HBV: standardization of nomenclature and assays and recommendations for management | |
| Le Gal et al. | Quantification of hepatitis delta virus RNA in serum by consensus real-time PCR indicates different patterns of virological response to interferon therapy in chronically infected patients | |
| Chen et al. | Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B | |
| Brichler et al. | Commercial real-time reverse transcriptase PCR assays can underestimate or fail to quantify hepatitis delta virus viremia | |
| Schwarze-Zander et al. | Role of GB virus C in modulating HIV disease | |
| Mixson-Hayden et al. | Performance of ARCHITECT HCV core antigen test with specimens from US plasma donors and injecting drug users | |
| EP2404933A3 (en) | HBV variants detection and application | |
| Gupta | Hepatitis C virus and HIV type 1 co-infection | |
| Jardi et al. | Analysis of hepatitis B genotype changes in chronic hepatitis B infection: Influence of antiviral therapy | |
| Mihm | Activation of type I and type III interferons in chronic hepatitis C | |
| HK1053144A1 (en) | Hepatitis b virus dna polymerase and surface antigen variants and methods of using same | |
| Lee et al. | Current laboratory tests for diagnosis of hepatitis B virus infection | |
| EP1609865A3 (en) | Hepatitis B virus (HBV) variants | |
| Pan et al. | Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine‐resistant hepatitis B genotypes B and C | |
| Gerken et al. | Clinical evaluation of a single reaction, diagnostic polymerase chain reaction assay for the detection of hepatitis C virus RNA | |
| Huang et al. | Analysis of clinical, biochemical and viral factors associated with early relapse after lamivudine treatment for hepatitis B e antigen‐negative chronic hepatitis B patients in Taiwan | |
| Huang et al. | Detectability and clinical significance of serum hepatitis B virus ribonucleic acid | |
| Gupta et al. | Analysis of mutations within the 5′ untranslated region, interferon sensitivity region, and PePHD region as a function of response to interferon therapy in hepatitis C virus-infected patients in India | |
| Santer et al. | A novel method for detection of IFN-lambda 3 binding to cells for quantifying IFN-lambda receptor expression |